Loading…
Ovid Therapeutics Inc. is projected to rise to $3.68 by 2027, a +46% move from its current price of $2.52. OVID is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.44 | $2.52 | $2.61 | +0.07% |
| Jul 14 | $2.41 | $2.52 | $2.64 | +0.14% |
| Jul 15 | $2.39 | $2.53 | $2.67 | +0.22% |
| Jul 16 | $2.37 | $2.53 | $2.70 | +0.29% |
| Jul 17 | $2.35 | $2.53 | $2.72 | +0.36% |
| Jul 18 | $2.33 | $2.53 | $2.74 | +0.43% |
| Jul 19 | $2.32 | $2.53 | $2.76 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.32 | $2.53 | $2.76 | +0.50% |
| Week 2 | $2.25 | $2.55 | $2.88 | +1.01% |
| Week 3 | $2.20 | $2.56 | $2.97 | +1.52% |
| Week 4 | $2.16 | $2.57 | $3.06 | +2.03% |
| Week 5 | $2.13 | $2.58 | $3.14 | +2.54% |
| Week 6 | $2.10 | $2.60 | $3.21 | +3.06% |
| Week 7 | $2.07 | $2.61 | $3.29 | +3.57% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ovid Therapeutics Inc. is a biopharmaceutical company that focuses on developing small molecule medicines for brain disorders, including epilepsies and seizure-related neurological disorders in the United States.
The company is developing OV329, a GABA-AT inhibitor in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with Parkinson's disease, Lewy body dementia, and acute schizophrenia.
It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID is currently trading at $2.52 per share and has a market capitalization of $469.4M.
It ranks 3090 in market listings. The near-term outlook is supported by a bullish technical posture as reflected in the price action and indicators.
Forecast data show a bullish multi-year trajectory, with the 2026 average price at $2.52 and the 2050 average at $47.22, indicating substantial long-term upside. By year, the forecast envisions the following progress: 2027 avg $3.67, 2028 avg $4.10, 2029 avg $4.81, 2030 avg $5.51, 2031 avg $6.01, 2032 avg $8.64, 2033 avg $10.61, 2034 avg $11.21, 2035 avg $13.48, 2040 avg $24.60, 2050 avg $47.22. The corresponding ROIs rise from 46% in 2027 to 1,777.7% by 2050, with sentiment transitioning from NEUTRAL in 2026 to BULLISH from 2027 onward.
A major floor 33.3% below — a decisive break under it would weaken the trend.
The nearest floor, 12.3% below — buyers have tended to step in here.
The nearest ceiling, 9.5% above — a clean break opens room to run.
A major ceiling 20.9% above — clearing it would confirm fresh momentum.
Key OVID support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OVID market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.64 | Sell | $2.61 | Sell |
| MA 10 | $2.65 | Sell | $2.60 | Sell |
| MA 20 | $2.49 | Buy | $2.56 | Sell |
| MA 50 | $2.56 | Sell | $2.51 | Buy |
| MA 100 | $2.39 | Buy | $2.35 | Buy |
| MA 200 | $1.97 | Buy | $2.02 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.92 | Neutral |
| Stoch RSI (14) | 38.81 | Neutral |
| CCI (20) | 11.06 | Neutral |
| Williams %R (14) | -47.06 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 8.62 | Buy |
| Bollinger %B (20,2) | 0.54 | Neutral |
| Stochastic %K (14) | 52.94 | Neutral |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | 0.16 | Buy |
| Ultimate (7,14,28) | 42.52 | Neutral |
| Momentum (10) | 0.10 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 2.63 | Sell |
| ADX (14) | 13.49 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bullish. The RSI(14) is 50, with the SMA50 at $2.56 and the SMA200 at $1.97, suggesting a constructive near-term bias.
Key support and resistance levels are $2.21 and $2.76, respectively, framing the immediate trading range. The 30-day range spans from $2.02 to $3.12, and the stock carries an annualized volatility of 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.42 | $2.52 | $3.49 | 0% | Neutral | |
| $2.87 | $3.68 | $5.02 | +46% | Bullish | |
| $3.10 | $4.11 | $5.85 | +63% | Bullish | |
| $3.53 | $4.82 | $7.09 | +91% | Bullish | |
| $3.95 | $5.53 | $8.37 | +119% | Bullish | |
| $4.20 | $6.01 | $9.33 | +139% | Bullish | |
| $5.91 | $8.64 | $13.71 | +243% | Bullish | |
| $7.12 | $10.64 | $17.21 | +322% | Bullish | |
| $7.37 | $11.23 | $18.50 | +345% | Bullish | |
| $8.69 | $13.49 | $22.61 | +435% | Bullish | |
| $14.57 | $24.65 | $44.31 | +878% | Bullish | |
| $23.98 | $47.28 | $94.05 | +17.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.42 | $2.52 | $3.02 | +0.00% |
| August 2026 | $2.19 | $2.60 | $3.18 | +3.16% |
| September 2026 | $2.25 | $2.69 | $3.33 | +3.49% |
| October 2026 | $2.19 | $2.65 | $3.31 | -1.65% |
| November 2026 | $2.16 | $2.62 | $3.31 | -1.08% |
| December 2026 | $2.24 | $2.73 | $3.49 | +4.47% |
Click any year to see its month-by-month OVID forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OVID is projected to trade between $1.42 and $3.49, averaging $2.52 — a potential gain of 0% from today's $2.52. A consolidation phase looks the most probable path here.
Ovid Therapeutics Inc.'s 2027 outlook centres on $3.68, within a $2.87 to $5.02 range. That is up +46% on the projected 2026 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2028, OVID could reach as high as $5.85, with a base case around $4.11 and support toward $3.10 — roughly +63% from $2.52. Buyers look set to stay in control over this stretch.
Expect OVID to range from $3.53 to $7.09 through 2029. The $4.82 average target implies a +91% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The OVID price prediction for 2030 points to an average of $5.53 (low $3.95, high $8.37) — a potential gain of +119% on today's $2.52. Buyers look set to stay in control over this stretch.
In 2031, OVID is projected to trade between $4.20 and $9.33, averaging $6.01 — a potential gain of +139% from today's $2.52. That is up +9% on the projected 2030 average. Momentum favours further upside here.
Ovid Therapeutics Inc.'s 2032 outlook centres on $8.64, within a $5.91 to $13.71 range. That is up +44% on the projected 2031 average. That marks a +243% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, OVID could reach as high as $17.21, with a base case around $10.64 and support toward $7.12 — roughly +322% from $2.52. Momentum favours further upside here.
Expect OVID to range from $7.37 to $18.50 through 2034. The $11.23 average target implies a +345% move from current prices. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The OVID price prediction for 2035 points to an average of $13.49 (low $8.69, high $22.61) — a potential gain of +435% on today's $2.52. Momentum favours further upside here.
In 2040, OVID is projected to trade between $14.57 and $44.31, averaging $24.65 — a potential gain of +878% from today's $2.52. That is up +83% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ovid Therapeutics Inc.'s 2050 outlook centres on $47.28, within a $23.98 to $94.05 range. That is up +92% on the projected 2040 average. That marks a +17.8x change versus current levels. Momentum favours further upside here.
Investing $1,000 in OVID today (≈ 396.825397 OVID) could be worth
$18,762.15
+$17,762.15 (+1776%) by 2050 · US Dollar
Based on the average projected OVID price of $47.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OVIDwould be worth at today's price.
$1,000 invested in OVID on Jul 10, 2025 (≈ 2,386.634846 OVID) would be worth
$6,014.32
+$5,014.32 (+501.4%) today · 6.01× · US Dollar
Based on a OVID entry price of $0.419 vs. today's $2.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.69 | $936.8 | -6.3% |
| 1 month ago | $2.28 | $1,105.26 | +10.5% |
| 3 months ago | $2.75 | $916.36 | -8.4% |
| 6 months ago | $1.61 | $1,565.22 | +56.5% |
| 1 year ago | $0.419 | $6,014.32 | +501.4% |
| All time (5.0y) ago | $3.83 | $657.96 | -34.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OVID forecast.
Our base-case forecast reaches $5.00 around 2030.
Implied market cap at $5.00: $933.2M
The multi-year forecast points to a persistent bullish trajectory, with the average price rising from $2.52 in 2026 to $5.51 in 2030 and up to $47.22 by 2050. The max values along the path extend to $8.35 in 2030 and as high as $93.94 by 2050, with ROIs of 119.2% (2030), 878.3% (2040), and 1,777.7% (2050).
Sentiment across the horizon strengthens from NEUTRAL in 2026 to BULLISH from 2027 through 2050, signaling a sustained uptrend according to the projection. These figures are estimates and not guarantees, and actual results depend on a range of factors not shown here.
Tap a question to reveal the answer.
2030 average price is $5.51 with a min of $3.94 and a max of $8.35; ROI is 119.2% and sentiment is BULLISH.
Forecasts indicate a bullish trajectory from 2027 onward with rising averages and ROIs (e.g., 2030 avg $5.51, 2030 max $8.35, 2040 avg $24.60, 2050 avg $47.22 and ROI up to 1,777.7%). These are estimates, not guarantees.
Current price is $2.52 per share and the market capitalization is $469.4M.
The 30-day range is $2.02 to $3.12.
Ovid Therapeutics Inc. Community Discussion
0Share your Ovid Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.